In 2019, Genenta Science initiated a phase I/II clinical trial (NCT03866109) using a single injection of autologous TEMs engineered to produce IFN-α (Temferon) in MGMT-unmethylated GBM patients. This evidence concerns the gene MGMT and glioblastoma.